We are pleased to announce that Allegrow Biotech has been selected for Precision Medicine P4 Cohort 8. P4 is a UK-based venture builder, accelerator, and fund supporting innovations in biotech and healthcare. As the UK's most active initiative in precision medicine, P4 has supported over 250 companies to date. The program provides mentorship, strategic guidance, and access to networks across the UK and European biotech ecosystem. This selection supports our expansion into the UK and European markets, building on the foundation we have established in Asia. With our Joel Yu currently pursuing his master's program in the UK, we are well-positioned to leverage the P4 network and engage closely with the cohort activities on the ground. We are excited to work with the P4 team and fellow Cohort 8 companies.
